Certified by Founder
Lodge
Myricx Bio
start up
United Kingdom
- London
- 09/07/2024
- Series A
- $115,246,800
We are a UK biotech company focused on the discovery and development of a completely novel class of selective cytotoxic payloads for antibody drug conjugates (ADCs), based on inhibitors of N-myristoyltransferases (NMT) for the treatment of cancer.
- Industry Biotechnology Research
- Website https://myricxbio.com/
- LinkedIn https://www.linkedin.com/company/myricx-pharma-ltd/
Autolane | $7,400,000 | (Dec 4, 2025)
Unacast | $28,000,000 | (Dec 4, 2025)
Ridley | $6,400,000 | (Dec 4, 2025)
Curi Bio | $10,000,000 | (Dec 4, 2025)
Supper | $11,000,000 | (Dec 4, 2025)
Gradium | $70,000,000 | (Dec 4, 2025)
Juniper Biosciences | $40,000,000 | (Dec 4, 2025)
Heven AeroTech | $100,000,000 | (Dec 4, 2025)
PineAI | $25,000,000 | (Dec 4, 2025)
TRIANA Biomedicines | $120,000,000 | (Dec 4, 2025)
Reema Health | $19,000,000 | (Dec 3, 2025)